1,506 Shares in Insulet Co. (NASDAQ:PODD) Purchased by Jump Financial LLC

Jump Financial LLC bought a new stake in Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,506 shares of the medical instruments supplier’s stock, valued at approximately $393,000.

Other institutional investors also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet in the fourth quarter worth $36,000. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Insulet by 30.1% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier’s stock worth $2,192,000 after purchasing an additional 1,942 shares during the last quarter. Ayrshire Capital Management LLC grew its position in Insulet by 34.6% in the 4th quarter. Ayrshire Capital Management LLC now owns 22,988 shares of the medical instruments supplier’s stock worth $6,001,000 after purchasing an additional 5,911 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Insulet by 21.8% during the 4th quarter. Jennison Associates LLC now owns 158,342 shares of the medical instruments supplier’s stock worth $41,338,000 after purchasing an additional 28,375 shares during the period. Finally, USA Financial Formulas acquired a new position in shares of Insulet during the fourth quarter valued at about $1,234,000.

Insulet Stock Up 0.5 %

Shares of NASDAQ PODD opened at $260.71 on Friday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company has a market cap of $18.31 billion, a price-to-earnings ratio of 45.03, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46. The firm’s 50-day simple moving average is $260.21 and its 200 day simple moving average is $261.49.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. On average, research analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares of the company’s stock, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.47% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on PODD shares. StockNews.com lowered Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Raymond James reissued an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Canaccord Genuity Group increased their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Wells Fargo & Company lifted their target price on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Finally, Stifel Nicolaus lifted their price objective on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.